Aldeyra Therapeutics Inc. - ALDX Net earnings per one share for the last twelve months

Aldeyra Therapeutics Inc. (ALDX) - corporate logo

Aldeyra Therapeutics (ALDX) develops treatments for allergies and dry eye, ensuring stable demand through the regular use of its solutions. Growth is driven by the FDA approval of reproxalap and the expansion of its metabolic drug portfolio. The company is currently actively preparing for the mass production of innovative products. The price action shown below confirms these data, and the EPS TTM stands at 56.00.

ALDX Aldeyra Therapeutics: Net earnings per share (EPS TTM) in the range 02/11/2024 - 11/18/2026

Aldeyra Therapeutics Inc. - analytical breakdowns and key metrics (ALDX)

- price and consensus price forecast:
Fundamental company valuation:ALDX, Aldeyra Therapeutics
Flagship merchandise of Aldeyra Therapeutics, Inc.

This indicator measures the rolling annual growth rate of earnings per share, neutralizing quarterly reporting gaps. Analyzing the 12-month YoY change in net income per share reveals the actual business dynamics, eliminating market illusions. For the investor, this serves as a tool for assessing capitalization efficiency. In Aldeyra Therapeutics (ALDX), such a metric reflects the financial results of elite ophthalmologists motivated by bonuses for successful clinical trials.

Direct competitors

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|KALA BIO, Inc. (KALA) - Net earnings per share (EPS TTM)|IRD (Opus Genetics Inc) - Net earnings per share (EPS TTM)|OKYO: Earnings per share for the trailing year|Net earnings per share for the last 12 months ADVM (adverum.com)|OTLK - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters